BMS: Insights Into Seropositive Rheumatoid Arthritis: A Path Towards Precision Medicine


Fassbender

Satellite Symposium
05 June 2020 08:15 - 09:45

Symposium objectives 

  • Establish biomarker-defined rheumatoid arthritis (RA) subtypes and discuss each subtype’s disease development and trajectory
  • Discuss the mechanisms by which effectors such as the shared epitope (SE), anti-citrullinated protein antibody (ACPA), and rheumatoid factor (RF) autoantibodies synergise in RA pathogenesis
  • Review the evidence of a differential treatment response to T-cell modulation by abatacept in certain RA patient populations, as demonstrated in clinical and real-world data


RA Is a Heterogenous Disease: How Can We Use Biomarkers to Define Subtypes?

  • Examine the heterogeneity of RA and how biomarkers can help define specific subtypes
  • Review the roles of biomarkers in RA pathogenesis and progression
  • Discuss the advantages of a biomarker-driven precision medicine approach to RA patient care

The Pathogenic Roles of the Shared Epitope and Autoantibodies in RA

  • Review the risk factors of seropositive RA development
  • Describe the properties of the SE and its role in antigen presentation
  • Examine the SE’s role as a genetic biomarker for ACPA+ RA, and review the evidence for its pathogenic implications in RA development and progression
  • Discuss the pathogenic mechanisms of autoantibodies in RA disease and progression

 The Case for a Precision Medicine Approach to RA Treatment Decisions

  • Discuss how targeting T-cell activation can help attenuate the pathology of effector biomarkers
  • Review the accumulating evidence for the differential efficacy of abatacept in certain patient populations and stages of RA
  • Develop the case for how treatment decisions in RA can be based on a precision medicine approach

Presentations

Title Time Add to calendar
BMS Symposium
05 June 2020 08:15 - 08:15 Add to calendar
Welcome and Introduction
05 June 2020 08:15 - 08:18 Add to calendar
RA Is a Heterogenous Disease: How Can We Use Biomarkers to Define Subtypes?
05 June 2020 08:18 - 08:31 Add to calendar
The Pathogenic Roles of the Shared Epitope and Autoantibodies in RA
05 June 2020 08:31 - 08:44 Add to calendar
The Case for a Precision Medicine Approach to RA Treatment Decisions
05 June 2020 08:44 - 08:57 Add to calendar
Symposium Summary and Close
05 June 2020 08:57 - 09:00 Add to calendar